Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission

Version 1 : Received: 20 June 2024 / Approved: 20 June 2024 / Online: 20 June 2024 (09:40:20 CEST)

How to cite: Atilano-Miguel, S.; Barbosa-Cortés, L.; Ortiz-Muñiz, R.; Maldonado-Hernández, J.; Martin-Trejo, J. A.; Rodríguez-Cruz, M.; Balcázar-Hernández, L.; Solís-Labastida, K. A.; Bautista-Martínez, B. A.; Juárez-Moya, A.; Hernández-Piñón, Z.; Galindo-Rodríguez, R. A.; Chávez Anaya, A.; Valdez-Avilez, R. E.; Domínguez-Salgado, J. M.; Villa-Morales, J.; Rodríguez-Palacios, M. E. Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission. Preprints 2024, 2024061413. https://doi.org/10.20944/preprints202406.1413.v1 Atilano-Miguel, S.; Barbosa-Cortés, L.; Ortiz-Muñiz, R.; Maldonado-Hernández, J.; Martin-Trejo, J. A.; Rodríguez-Cruz, M.; Balcázar-Hernández, L.; Solís-Labastida, K. A.; Bautista-Martínez, B. A.; Juárez-Moya, A.; Hernández-Piñón, Z.; Galindo-Rodríguez, R. A.; Chávez Anaya, A.; Valdez-Avilez, R. E.; Domínguez-Salgado, J. M.; Villa-Morales, J.; Rodríguez-Palacios, M. E. Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission. Preprints 2024, 2024061413. https://doi.org/10.20944/preprints202406.1413.v1

Abstract

Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption; disruptions in this complex can affect bone metabolism. Methods: This study analyzed the changes in RANKL, OPG and 25(OH)D levels, the RANKL/OPG ratio, and other bone turnover markers (BTM) from diagnosis to complete remission in children with acute lym-phoblastic leukemia (ALL). This is a prospective observational cohort study. This study was carried out in the Instituto Mexicano del Seguro Social in Mexico City. Thirty-three patients (4-17 years) with newly diagnosed B-cell ALL were included. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A pe-ripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p=0.001) and osteocalcin (p

Keywords

Acute lymphoblastic leukemia; RANK Ligand; Osteoprotegerin; 25(OH)D; Corticosteroids; Bone turnover markers

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.